Overview
CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).
Background
CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).
Indication
用于治疗既往未接受过全身系统性治疗的不可手术切除或转移性肝细胞癌患者。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/11/12 | Phase 2 | Recruiting | |||
2024/10/17 | Phase 2 | Recruiting | Fei Gao | ||
2024/09/24 | Not Applicable | Recruiting | Sun Yat-sen University | ||
2024/09/03 | Not Applicable | Recruiting | |||
2024/07/22 | Phase 2 | Not yet recruiting | |||
2024/07/12 | Phase 2 | Recruiting | Anhui Provincial Hospital | ||
2024/07/11 | Phase 4 | Not yet recruiting | |||
2024/07/01 | Phase 2 | Recruiting | |||
2024/02/02 | Phase 1 | Recruiting | |||
2024/01/31 | Not Applicable | Not yet recruiting | Changsha Taihe Hospital |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Donafenib Tosilate Tablets | 国药准字H20210020 | 化学药品 | 片剂 | 8/10/2022 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||